Phio Pharmaceuticals (PHIO) Amortizatization of Intangibles (2019 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Amortizatization of Intangibles came in at $33000.0 in Q1 2024, up 6.45% on a YoY basis from $31000.0 in Q2 2023, and little changed quarter-over-quarter from $33000.0 in Q4 2023.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Amortizatization of Intangibles (2019 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Amortizatization of Intangibles for 6 consecutive years, with $33000.0 the latest figure, recorded in Q1 2024.
- For the quarter ending Q1 2024, Amortizatization of Intangibles rose 6.45% year-over-year to $33000.0; the trailing twelve-month figure through Dec 2024 stood at $33000.0 (down 74.22% YoY), and the FY2024 full-year result was $33000.0, down 74.22% from the prior year.
- Amortizatization of Intangibles held at $33000.0 in Q1 2024 per PHIO's latest filing, from $33000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $33000.0 in Q4 2023 and bottomed at $27000.0 in Q1 2020.
- Historically, Amortizatization of Intangibles has averaged $30058.8 across 5 years, with a median of $30000.0 in 2021.
- The sharpest annual moves came in 2020 and 2021: Amortizatization of Intangibles dropped 3.57% in 2020, then increased 7.41% in 2021.
- Over 5 years, Amortizatization of Intangibles stood at $28000.0 in 2020, then gained by 7.14% to $30000.0 in 2021, then grew by 3.33% to $31000.0 in 2022, then grew by 6.45% to $33000.0 in 2023, then changed by 0.0% to $33000.0 in 2024.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $33000.0, $33000.0, and $32000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Dec 31, 2022 | 31,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 30,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2021 | 29,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Mar 31, 2021 | 29,000.00 |
| Dec 31, 2020 | 28,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 28,000.00 |
| Mar 31, 2020 | 27,000.00 |
| Dec 31, 2019 | 27,000.00 |
| Sep 30, 2019 | 27,000.00 |
| Jun 30, 2019 | 27,000.00 |